Research Article

Tinosaponin AIII Suppresses RAP1 Signaling Pathway to Enhance the Inhibitory Effect of Paclitaxel on Nasopharyngeal Carcinoma

Xiaofeng Li,¹ Wen Lu,¹ Tianjiao Zhou,¹ Feng Zhao,¹ and Li Yang²

¹Department of Otorhinolaryngology, Head and Neck Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
²Department of Head and Neck Surgery, People’s Hospital of Guang’an City, Guang’an 638001, China

Correspondence should be addressed to Li Yang; yang2323492@163.com

Received 19 January 2022; Revised 14 April 2022; Accepted 22 April 2022; Published 9 May 2022

Academic Editor: Shakeel Ahmad

Copyright © 2022 Xiaofeng Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although PTX has been identified as an effective drug for nasopharyngeal carcinoma (NPC) therapy, it has serious side effects in the human body. Previous studies have shown that tinosaponin AIII (TSAIII) can inhibit the malignant progression of NPC cells. This study investigated the active mechanism of the combination of TSAIII and paclitaxel (PTX) on NPC. Cellular viability, apoptosis, apoptotic factors, and RAP1 signaling regulators were detected in the PNC cells (CNE-1 and HNE-2) and the subcutaneous CNE-1 transplanted nude mice treated with PTX or/and TSAIII. The results showed that TSAIII notably strengthened the inhibitory effect of PTX on the proliferation of NPC cells CNE-1 and HNE-2; upregulated the expression of Bax B-cell lymphoma 2 (Bcl-2)/Bcl-xL-associated death promoter (Bad), and Ras-associated protein1 (RAP1) GTPase activating protein (Rap1GAP); inhibited the level of Bcl-2, RAP1, and Ras guanine nucleotide releasing protein (RasGRP2); and significantly enhanced the promoting effect of PTX on apoptosis in the CNE-1 and HNE-2 cells. Besides, TSAIII strengthened the inhibitory effect of PTX on xenograft tumor in nude mice without adverse reactions. In conclusion, the combination administration of TSAIII and PTX had a significantly therapeutic effect on NPC and avoided the PTX’s side effects, which may have acted as a new direction for the study of therapeutic approaches for NPC clinically.

1. Introduction

Nasopharyngeal carcinoma (NPC) is a malignant tumor that occurs in the superior wall (roof) and medial wall of the nasopharyngeal cavity. NPC has an insidious onset and the incidence ranks first among ear, nose, and throat malignancies [1]. Most NPC patients have a more dangerous prognosis due to late diagnosis. So far, radiotherapy is the main treatment manner for NPC. Chemotherapy is regarded as a supplement treatment. However, it is not applicable for patients with advanced NPC because both radiotherapy and chemotherapy can lead to drug tolerance [2]. Despite advanced radiotherapy and chemotherapy techniques now, the 5-year survival rate of the patients with NPC has not been significantly improved yet [3]. Therefore, it is urgent to find a way with high efficacy and less side effects for the treatment of NPC.

Paclitaxel (PTX) belongs to diterpenoid alkaloid compounds, which has been confirmed as the new generation of cancer chemotherapy drug clinically [4]. Clinical studies have confirmed that patients receiving PTX chemotherapy are often prone to various side effects, such as neuropathic pain and myelosuppression [5]. It is reported that drug combination can significantly improve therapeutic efficacy and reduce side effects in the treatment of NPC [6]. Zhou et al. recently showed that some traditional Chinese medicine (TCM) monomers can enhance the antitumor effect of PTX [7]. Hence, the combination of...
2.2. Cellular Viability Assay. The CCK-8 kit (Abcam, Cambridge, United Kingdom) was utilized for the analysis of cellular viability. Firstly, CNE-1 and HNE-2 cells with a density of \( \times 10^5 \) cells/mL were seeded in a 96-well plate. After adherence of the cells, TSAIII (0, 10, 20, 40, 80, and 120 μM) and/or PTX (0, 2, 4, 8, 16, and 32 μM) were added in the cells respectively for 72-hour incubation. Subsequently, each well was added 10 μL of CCK-8 reagent for another 4-hour incubation. Then, Synergy HTX Multi-Mode Reader (Agnent Technologies: Richmond, TX) was applied to detect absorbance values of the solutions at 450 nm.

2.3. Apoptosis Assay. The cells were treated by TSAIII (10 μM) and/or PTX (8 μM). After 72 h, the cells were digested using trypsin and then collected, washed with pre-cooled PBS, and suspended with 1x binding buffer. Subsequently, the cells were mixed with 5 μL of annexin V-FITC or/and 5 μL of propidium iodide (PI) under a light avoidance condition at ambient temperature for 15 min. After adding 1x binding buffer for the resuspension of the cells, flow cytometry was conducted for the detection of apoptosis.

2.4. RT-qPCR. TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was adopted to extract total RNA from the detecting cells. Following, according to the instruction of PrimeScript RT kit (TaKaRa, Tokyo, Japan), mRNA was reverse transcribed into cDNA. The expression of mRNA were determined by RT-qPCR with SYBR green I Master Mix kits (Invitrogen) using corresponding primers (Table 1). In 7500 real-time PCR system (Applied Biosystems, America), GAPDH acted as the internal control.

### Table 1

| Gene   | Primer sequence (5'-3') |
|--------|------------------------|
| Bax    | Forward: 5'-CCCGAGAGGTCTTTTACGGG-3'  
Revers: 5'-CCACGAGATGTTCTGTGAT-3' |
| Bad    | Forward: 5'-CCCAGAGTTTGAAGCGAGTG-3'  
Revers: 5'-CCCATCTCTTTCGTCCTC-3' |
| Bcl-2  | Forward: 5'-CGGTTCAGGTACTGATCCTAC-3'  
Revers: 5'-GGTGAGGTCATGTGTGG-3' |
| RAP1   | Forward: 5'-GCCGAAGGACCTTGTCGG-3'  
Revers: 5'-ACTATGGGCTAGAGCACAGA-3' |
| RAP1GAP| Forward: 5'-CTACACGGAAGCCTTGTCG-3'  
Revers: 5'-CACACACCACTTTCGTC-3' |
| RasGRP2| Forward: 5'-AACATCCGGAGGAAGACTC-3'  
Revers: 5'-GGTATTGTCATTAGGCTGTCG-3' |
| GAPDH | Forward: 5'-GCACCCTCAGGCTGAGAC-3'  
Revers: 5'-TGGTGAAGAGCCCACTGGA-3' |

2.5. Experimental Animal. Shanghai Animal Center (Shanghai, China) provided 20 chargeable male BALB/nude mice (age: 4-6 weeks). Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University approved the animal experiments. And the animal experiments were performed according to the National Institutes of Health Guidelines for Animal Care.

Twenty male BALB/nude mice (age: 4-6 weeks) (Shanghai Animal Center, Shanghai, China) were randomly divided into control, PTX (10 mg/kg), TSAIII (40 mg/kg), and PTX +TSAIII groups (five mice/group). All the mice were injected subcutaneously with 100 μL of phosphate buffer saline (PBS) containing 5 × 10^6 CNE-1 cells in the right axillary region. After four weeks raise, the tumor volume was calculated as 1/2 × (length × width^2). Four weeks later, the mice were sacrificed. The mice’ bodies and the tumor were weighed and recorded. Partial tumor tissues were fixed in 4% of paraformaldehyde for H&E and immunohistochemical staining analyses.

2.6. Statistical Analysis. All experiments were independently repeated three times. The statistical analysis of the data was conducted with SPSS 24.0 (IBM-SPSS, Chicago, IL, USA). And the data was presented as mean ± standard deviation (SD). Student’s t-test and one-way analysis of variance were carried out for the comparisons between two groups and among multiple groups, respectively. The differences were
regarded to be significant if $P < 0.05$. All data presentations were plotted with GraphPad Prism 7.0 software (GraphPad Software, San Diego, CA, USA).

3. Results

3.1. TSAIII Strengthened the Inhibitory Effect of Paclitaxel on the Proliferation of NPC Cells. To examine the effect of TSAIII combined with PTX on NPC development, different concentrations of TSAIII and PTX were utilized to treat CNE-1 and HNE-2 cells in vitro. The TSAIII structure was shown in Figure 1(a). Cellular proliferation test revealed that both TSAII and PTX significantly suppressed the cellular proliferation of either HNE-2 or CNE-1 cells in a dose-dependent manner ($P < 0.05$) (Figures 1(b) and 1(c)). Moreover, the inhibitory effect of PTX on the proliferation of CNE-1 and HNE-2 cells was more significant at a concentration of 8 $\mu$M ($P < 0.01$) (Figure 1(c)); therefore, the concentration of PTX was determined to be 8 $\mu$M in subsequent experiments. Further treatment of the CNE-1 and the HNE-2 cells with both TSAIII and PTX at the same time revealed that the inhibitory effect of the PTX on the cellular proliferation was notably enhanced by TSAIII ($P < 0.05$) (Figure 1(d)) with a dose-dependent manner. These data expressed that TSAIII combined with PTX had a synergistic effect on cellular proliferative inhibition in the CNE-1 and the HNE-2 cells.

3.2. TSAIII Strengthened the Promoting Effect of PTX on Apoptosis of CNE-1 and HNE-2 cells. To further testify the synergistic effect of TSAIII on the PTX-caused NPC progression, flow cytometry was conducted to detect the cellular apoptosis. The results of the detection indicated that PTX alone significantly promoted cellular apoptosis of CNE-1 and HNE-2 ($P < 0.05$). And the apoptosis was notably higher in the TSAIII+PTX group than that in the PTX or TSAIII alone group ($P < 0.05$) (Figure 2(a)). Western blot detection of the apoptosis-related proteins showed that PTX alone obviously increased Bax and B-cell lymphoma 2 (Bcl-2)/Bcl-xL-associated death promoter (Bad) expression and significantly decreased Bcl-2 expression ($P < 0.05$). Notably, simultaneous supplement with TSAIII strengthened the regulative effect of PTX on the apoptotic proteins. The protein expression of Bax and Bad was further increased, while Bcl-2 expression was further decreased ($P < 0.05$) (Figure 2(b)). These results indicated that TSAIII had a synergistic role in the proapopotic activity of PTX in the CNE-1 and HNE-2 cells.

3.3. TSAIII Strengthened the Anti-NPC Effect of PTX by Modulating RAPI Pathway. The mechanism of the synergistic action of TSAIII and PTX was further investigated. Rap1 is reported to potentially regulate oncogenesis, metastasis, immune evasion, and chemoresistance [24]. RT-qPCR analysis revealed that both PTX and TSAIII could significantly
increase the gene expression of RAP1GAP and reduce the expression of RAP1 and RasGRP2 ($P < 0.05$). Interestingly, the combination of TSAIII and PTX had an enhanced effect on the above gene expression compared with single use of either TSAIII or PTX ($P < 0.05$) (Figures 3(a) and 3(b)), disclosing that the increased inhibitory effect of the combination of TSAIII and PTX on NPC was related to the inhibition of the RAP1 pathway.

3.4. TSAIII and PTX Exerted a Synergistic Antitumor Activity In Vivo. A xenograft mouse model was utilized to validate the synergistic antitumor effect of TSAIII and PTX in vivo. The results showed that either PTX or TSAIII obviously reduce tumor volume and weight ($P < 0.05$). The inhibitory effect of the combination of PTX with TSAIII on tumor growth was significantly increased ($P < 0.05$) (Figures 4(a)–4(c)). Besides, the weight of the mice in the combined treatment group was not significantly different compared with the control group ($P > 0.05$). These data indicated that combination of PTX with TSAIII had less side effects on the mice (Figure 4(d)). All results above suggested that the synergistic antitumor effect of the combination of TSAIII with PTX was verified as well in vivo.

3.5. TSAIII Promoted the PTX-Induced Effects on Cellular Apoptosis in Tumor Tissues In Vivo. H&E staining and immunohistochemical assays were processed to determine the cellular apoptosis in the tumor tissues. The H&E staining showed that the apoptotic cells in tumor tissues declined significantly in the TSAIII+PTX group compared with the single administration of either the TSAIII or PTX group (Figure 5(a)). Besides, the immunohistochemical assays also revealed that the combination of TSAIII with PTX further increased the expression of caspase-3 and Bax in tumor tissues compared with the single administration of either TSAIII or PTX (Figures 5(b) and 5(c)). All the in vivo experimental results above demonstrated that TSAIII enhanced the induced effects of PTX on cellular apoptosis in tumor tissues.

4. Discussion

It’s reported that the most widely applied anticancer drug at present is PTX. However, the resistance of the PTX can cause the failure of the treatment for the cancers [25]. Chen et al. have reported that TCM monomers combined with
Figure 3: Effect of combination of TSAII and PTX on RAP1 pathway-regulating factors in the NPCs. RT-qPCR was applied to analyze the mRNA levels of RAP1 pathway-regulating factors in the indicated group of CNE-1 (a) and HNE-2 (b) cells. **P < 0.01 vs. the control group; ##P < 0.01 vs. 8 μM PTX or 10 μM TSAIII.

Figure 4: Effect of TSAIII combined with PTX on the growth of transplanted PNC tumor in nude mice. Images showed the tumor size (a), volume (b), weight (c), and nude mice weight (n = 5) (d) 4 weeks after inoculation of the xenografts tumor in nude mice at the indicated conditions. **P < 0.01 vs. the control group; #P < 0.05 vs. 10 mg/kg PTX or 40 mg/kg TSAIII.
PTX have been applied as an alternative therapy for the tumors and got good results [26]. In this study, we found that TSAIII significantly strengthened the inhibitory effect of PTX on the NPC growth and metastasis via decreasing the cellular proliferation and increasing the cellular apoptosis in vitro and in vivo. Detail study of the anti- and proapoptotic regulator balance revealed that TSAIII upregulated the expression level of Bax and Bad but declined the expression level of Bcl-2. Usually, the antiapoptotic and proapoptotic protein regulator balance is a critical important to decide whether the cells go through apoptosis. Deregulation of apoptosis is believed to be one of the cancer’s hallmarks [27]. Both Bax and Bad are the crucial proapoptotic regulators, while Bcl-2 is an important antiapoptotic factor. All of them are involved in the regulation of extrinsic apoptotic pathway [28]. Thus, TSAIII strengthened the antioncogenesis of PTX on the NPCs through downregulation of Bax and Bad and upregulation of Bcl-2 to improve the NPC apoptosis. We noticed that either PTX or TSAIII alone exhibited the antitumor activity via Bax and Bad inhibition and Bcl-2 elevation to prohibit PNC proliferation and improve apoptosis. Interestingly, the combination of PTX with TSAIII created more effective antitumor activity than single use of either PTX or TSAIII, mechanically, which revealed more inhibitory effect on Bax and Bad, but more activation power on Bcl-2 to much inhibit proliferation and much improve apoptosis in the PNCs. More importantly, combination administration of PTX with TSAIII did not show obvious side effects in the xenograft mouse model assay, because the body weight between the PTX+TSAIII group and either PTX or TSAIII group did not have any significant difference.

RAP1 is a GTPase protein that can interact with other proteins to regulate physiological and pathological processes such as migration, invasion, and metastasis of tumor cells [29–31]. Lost control of the RAP1 signal is associated with tumor growth and metastasis. RAP1 signaling activation is reported in many types of cancers [18–20, 22]. Inactivation form of RAP1 (RAP1-GDP) is positively regulated by guanine nucleotide exchange factors (GEFs), including cAMP, Epac, C3G, RapGRP2, and PDZ-GEF, to form a Rap1-GTP (activation form). On the other hand, the activated form of Rap1-GTP is negatively regulated by GTPase activation proteins (GAPs), including Rap1GAP and SPA-1 [24]. Our data showed that combination of the PTX with TSAIII improved the inhibitory effect of RAP1 and RasGRP2 induced by either PTX or TSAIII alone, further inhibiting the PNC growth. It has been shown that CD38 can promote RasGRP2/RAP1-mediated adhesion and migration of chronic lymphocytic leukemia cells by increasing intracellular Ca²⁺ levels [32]. However, either PTX or TSAIII also revealed the prohibited activity on Rap1-GAP. A study shows Rap1GAP as a tumor suppressor can inhibit the development and progression of many tumors [33, 34]. Therefore, the balance of RasGRP2 and RAP1 with Rap1-GAP will decide the tumor direction.
Thus, our results verified that TSAIIII inhibited PNC growth via the inhibition of the RAP1 pathway in CNE-1 and HNE-2 cells, thereby playing a synergistic role with PTX to prohibit NPC cells. The combined treatment of TSAIIII and PTX further emphasized the proapoptotic effect of PTX via RAP1 pathway suppression in NPC cells.

In summary, it is found in this study that, in vitro and in vivo, TSAIIII has enhanced the anti-tumor effect of PTX on NPC cells. The combination of TSAIIII and PTX offers a new research direction for the clinical treatment of NPC. The limitation of this study is the lack of a systemic examination of the side effect of the PTX+TSAIIII combination on the hematological, hepatic, renal, and cardiological systems in the xenograft mouse model.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no competing interests.

References

[1] Y. P. Chen, A. T. Chan, Q. T. Le, P. Blanchard, Y. Sun, and J. Ma, “Nasopharyngeal carcinoma,” Lancet, vol. 394, no. 10192, pp. 64–80, 2019.
[2] W. K. J. Lam and J. Y. K. Chan, “Recent advances in the management of nasopharyngeal carcinoma,” F1000Research, vol. 7, 2018.
[3] L. F. Wang, C. Y. Chai, W. R. Kuo, C. F. Tai, K. W. Lee, and K. Y. Ho, “Correlation between proliferating cell nuclear antigen and p 53 protein expression and 5-year survival rate in nasopharyngeal carcinoma,” American Journal of Otolaryngology, vol. 27, no. 2, pp. 101–105, 2006.
[4] N. I. Marupudi, J. E. Han, K. W. Li, V. M. Renard, B. M. Tyler, and H. Brem, “Paclitaxel: a review of adverse toxicities and novel delivery strategies,” Expert Opinion on Drug Safety, vol. 6, no. 5, pp. 609–621, 2007.
[5] S. P. Bisch, A. Sugimoto, M. Prefontaine et al., “Treatment tolerance and side effects of intraperitoneal carboplatin and dozedense intravenous paclitaxel in ovarian cancer,” Journal of Obstetrics and Gynaecology Canada, vol. 40, no. 10, pp. 1283–1287, 2018.
[6] A. Davenport, M. Frezza, M. Shen et al., “Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells,” International Journal of Molecular Medicine, vol. 25, no. 3, pp. 465–470, 2010.
[7] L. Zou, X. Liu, J. Li et al., “Tetramethylpyrazine enhances the antitumor effect of paclitaxel by inhibiting angiogenesis and inducing apoptosis,” Front Pharmacol, vol. 10, article 707, 2019.
[8] F. Y. Han, X. Y. Song, J. J. Chen, G. D. Yao, and S. J. Song, “Timosaponin AIII: a novel potential anti-tumor compound from Anemarrhena asphodeloides,” Steroids, vol. 140, pp. 125–130, 2018.
[9] Y. Wang, L. Xu, L. L. Lou et al., “Timosaponin AIII induces apoptosis and autophagy in human melanoma A375-S2 cells,” Archives of Pharmacal Research, vol. 40, no. 1, pp. 69–78, 2017.
[10] K. M. Kim, A. R. Im, S. H. Kim, J. W. Hyun, and S. Chae, “Timosaponin AIII inhibits melanoma cell migration by suppressing COX-2 and in vivo tumor metastasis,” Cancer Science, vol. 107, no. 2, pp. 181–188, 2016.
[11] Y. J. Kang, H. J. Chung, J. W. Nam et al., “Cytotoxic and anti-neoplastic activity of timosaponin A-III for human colon cancer cells,” Journal of Natural Products, vol. 74, no. 4, pp. 701–706, 2011.
[12] C. H. Tsai, C. W. Yang, J. Y. Wang et al., “Timosaponin AIII suppresses hepatocyte growth factor-induced invasive activity through sustained ERK activation in breast cancer MDA-MB-231 cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 421051, 10 pages, 2013.
[13] O. Jung and S. Y. Lee, “Synergistic anticancer effects of timosaponin AIII and ginsenosides in MG63 human osteosarcoma cells,” Journal of Ginseng Research, vol. 43, no. 3, pp. 488–495, 2019.
[14] A. Banno and M. H. Ginsberg, “Integrin activation,” Biochemical Society Transactions, vol. 36, no. 2, pp. 229–234, 2008.
[15] H. Harjunpää, M. Llort Asens, C. Guenther, and S. C. Fagerholm, “Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment,” Front Immunology, vol. 10, p. 1078, 2019.
[16] M. Alemayehu, M. Dragan, C. Pape et al., “β-Arrestin 2 regulates lysophosphatidic acid-induced human breast tumor cell migration and invasion via Rap 1 and IQGAP1,” PLoS One, vol. 8, no. 8, article e65174, 2013.
[17] Y. Yang, M. Li, Y. Yan et al., “Expression of RAP1B is associated with poor prognosis and promotes an aggressive phenotype in gastric cancer,” Oncol Reports, vol. 34, no. 5, pp. 2385–2394, 2015.
[18] C. L. Bailey, P. Kelly, and P. J. Casey, “Activation of Rap 1 promotes prostate cancer metastasis,” Cancer Research, vol. 69, no. 12, pp. 4962–4968, 2009.
[19] J. Sayyah, A. Bartakova, N. Nagai, L. A. Quilliam, D. G. Stupack, and J. H. Brown, “The Ras-related protein, Rap 1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth,” Journal of Biological Chemistry, vol. 289, no. 25, pp. 17689–17698, 2014.
[20] L. Xiao, X. Lan, X. Shi et al., “Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer,” Cell Death & Disease, vol. 8, no. 5, article e2803, 2017.
[21] S. Zhou, Y. Liang, X. Zhang et al., “SHARPIN promotes melanoma progression via Rap 1 signaling pathway,” Journal of Investigative Dermatology, vol. 140, no. 2, pp. 395–403, 2020.
[22] E. A. McSherry, K. Brennan, L. Hudson, A. D. Hill, and A. M. Hopkins, “Breast cancer cell migration is regulated through junctional adhesion molecule-a-mediated activation of Rap 1 GTPase,” Breast Cancer Research, vol. 13, no. 2, pp. 1–14, 2011.
[23] M. Huang, S. Anand, E. A. Murphy et al., “EGFR-dependent pancreatic carcinoma cell metastasis through Rap 1 activation,” Oncogene, vol. 31, no. 22, pp. 2783–2793, 2012.
[24] C. K. Looi, L. W. Hii, S. C. Ngai, C. O. Leong, and C. W. Mai, “The role of Ras-associated protein 1 (Rap 1) in cancer: bad actor or good player?,” Biomedicines, vol. 8, no. 9, article 334, 2020.
[25] T. M. Abu Samaan, M. Samec, A. Liskova, P. Kubatka, and D. Büsselberg, “Paclitaxel’s mechanistic and clinical effects on breast cancer,” Biomolecules, vol. 9, no. 12, article 789, 2019.
[26] Y. Chen, L. Wang, H. Liu et al., “PET imaging on dynamic metabolic changes after combination therapy of paclitaxel and the traditional Chinese medicine in breast cancer-bearing mice,” *Molecular Imaging and Biology*, vol. 20, no. 2, pp. 309–317, 2018.

[27] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” *Cell*, vol. 144, no. 5, pp. 646–674, 2011.

[28] G. Pistritto, D. Trisciuoglio, C. Ceci, A. Garufi, and G. D’Orazi, “Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies,” *Aging*, vol. 8, no. 4, pp. 603–619, 2016.

[29] F. McCormick, “Ras-related proteins in signal transduction and growth control,” *Molecular Reproduction and Development*, vol. 42, no. 4, pp. 500–506, 1995.

[30] Y. Shibayama, Y. Kubo, T. Nakagawa, and K. Iseki, “Micro RNA-101-5p suppresses the expression of the Ras-related protein RAP1A,” *Biological and Pharmaceutical Bulletin*, vol. 42, no. 8, pp. 1332–1336, 2019.

[31] Y. L. Zhang, R. C. Wang, K. Cheng, B. Z. Ring, and L. Su, “Roles of Rap 1 signaling in tumor cell migration and invasion,” *Cancer Biology & Medicine*, vol. 14, no. 1, pp. 90–99, 2017.

[32] S. Mele, S. Devereux, A. G. Pepper, E. Infante, and A. J. Ridley, “Calcium-Ras GRP2-Rap 1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells,” *Blood Advances*, vol. 2, no. 13, pp. 1551–1561, 2018.

[33] M. Tamate, R. Tanaka, H. Osogami et al., “Rap1GAP inhibits tumor progression in endometrial cancer,” *Biochemical and Biophysical Research Communications*, vol. 485, no. 2, pp. 476–483, 2017.

[34] B. Faam, M. A. Ghaffari, L. Khorsandi et al., “RAP1GAP functions as a tumor suppressor gene and is regulated by DNA methylation in differentiated thyroid cancer,” *Cytogenetic and Genome Research*, vol. 161, no. 5, pp. 227–235, 2021.